245 related articles for article (PubMed ID: 25261754)
21. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
22. Activation of α7-nAChRs protects SH-SY5Y cells from 1-methyl-4-phenylpyridinium-induced apoptotic cell death via ERK/p53 signaling pathway.
Xu S; Yang B; Tao T; Zhang J; Liu Y; Hu J; Fan Y; Zhang G
J Cell Physiol; 2019 Aug; 234(10):18480-18491. PubMed ID: 30912145
[TBL] [Abstract][Full Text] [Related]
23. Multiple roles for nicotine in Parkinson's disease.
Quik M; Huang LZ; Parameswaran N; Bordia T; Campos C; Perez XA
Biochem Pharmacol; 2009 Oct; 78(7):677-85. PubMed ID: 19433069
[TBL] [Abstract][Full Text] [Related]
24. Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.
Brunzell DH; McIntosh JM; Papke RL
Ann N Y Acad Sci; 2014 Oct; 1327(1):27-45. PubMed ID: 24730978
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
26. Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.
Ryan RE; Ross SA; Drago J; Loiacono RE
Br J Pharmacol; 2001 Apr; 132(8):1650-6. PubMed ID: 11309235
[TBL] [Abstract][Full Text] [Related]
27. Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle.
Visanji NP; O'Neill MJ; Duty S
Neuropharmacology; 2006 Sep; 51(3):506-16. PubMed ID: 16814329
[TBL] [Abstract][Full Text] [Related]
28. Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.
Marks MJ; Wageman CR; Grady SR; Gopalakrishnan M; Briggs CA
Biochem Pharmacol; 2009 Oct; 78(7):795-802. PubMed ID: 19481067
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists.
Jonnala RR; Buccafusco JJ
J Neurosci Res; 2001 Nov; 66(4):565-72. PubMed ID: 11746376
[TBL] [Abstract][Full Text] [Related]
30. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
[TBL] [Abstract][Full Text] [Related]
31. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
32. Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease.
Quik M; Zhang D; McGregor M; Bordia T
Biochem Pharmacol; 2015 Oct; 97(4):399-407. PubMed ID: 26093062
[TBL] [Abstract][Full Text] [Related]
33. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
[TBL] [Abstract][Full Text] [Related]
34. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Huang LZ; Campos C; Ly J; Ivy Carroll F; Quik M
Neuropharmacology; 2011 May; 60(6):861-8. PubMed ID: 21232546
[TBL] [Abstract][Full Text] [Related]
35. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
36. α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.
Marks MJ; Grady SR; Salminen O; Paley MA; Wageman CR; McIntosh JM; Whiteaker P
J Neurochem; 2014 Jul; 130(2):185-98. PubMed ID: 24661093
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
El Nebrisi E; Javed H; Ojha SK; Oz M; Shehab S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023066
[TBL] [Abstract][Full Text] [Related]
38. In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease.
Abin-Carriquiry JA; Costa G; Urbanavicius J; Cassels BK; Rebolledo-Fuentes M; Wonnacott S; Dajas F
Eur J Pharmacol; 2008 Jul; 589(1-3):80-4. PubMed ID: 18589414
[TBL] [Abstract][Full Text] [Related]
39. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.
Parikh V; Ji J; Decker MW; Sarter M
J Neurosci; 2010 Mar; 30(9):3518-30. PubMed ID: 20203212
[TBL] [Abstract][Full Text] [Related]
40. Nicotinic acetylcholine receptors regulate clustering, fusion and acidification of the rat brain synaptic vesicles.
Trikash I; Kasatkina L; Lykhmus O; Skok M
Neurochem Int; 2020 Sep; 138():104779. PubMed ID: 32474177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]